Penetration of dapsone into cerebrospinal fluid of patients with AIDS

Journal of Antimicrobial Chemotherapy

Volumn 40, Issue 1, 1997, Pages 113-115

  Gatti, Giorgio ^a,c   Hossein, Javad ^a   Malena, Marina ^b   Cruciani, Mario ^b   Bassetti, Matteo ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DAPSONE; LEPROSTATIC AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CEREBROSPINAL FLUID; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG PENETRATION; FEMALE; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PNEUMOCYSTIS PNEUMONIA;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; DAPSONE; FEMALE; HUMANS; MALE; MIDDLE AGED; PNEUMONIA, PNEUMOCYSTIS;

EID: 0030841072     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/40.1.113     Document Type: Article

References (10)

1. Antinori, A., Murri, R., Ammassari, A., De Luca, A., Linzalone, A., Cingolani, A. et al. (1995). Aerosolized pentamidine, cotrimoxazole and dapsone-pyrimethamine for primary prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis. AIDS 9, 1343-50.
2. Girard, P.-M., Landman, R., Gaudebout, C., Olivares, R., Saimot, A. G., Jelazko, P. et al. (1993). Dapsone-pyrimethamine compared with aerosolized pentamidine as primary prophylaxis against Pneumocystis carinii pneumonia and toxoplasmosis in HIV infection. New England Journal of Medicine 328, 1514-20.
3. Opravil, M., Hirschel, B., Lazzarin, A., Heald, A., Pechère, M., Ruttimann, S. et al. (1995). Once-weekly administration of dapsone/ pyrimethamine vs. aerosolized pentamidine as combined prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus-infected patients. Clinical Infectious Diseases 20, 531-41.
4. Clumeck, N. (1991). Some aspects of the epidemiology of toxoplasmosis and pneumocystosis in AIDS in Europe. European Journal of Clinical Microbiology & Infectious Diseases 10, 177-8.
5. Gatti, G., Loy, A., Casazza, R., Miletich, F., Cruciani, M. & Bassetti, D. (1995). Pharmacokinetics of dapsone in human immunodeficiency virus-infected children. Antimicrobial Agents and Chemotherapy 39, 1101-6.
6. Rich, J. D., Sax, P. E. & Mirochnick, M. (1994). Dapsone penetrates CSF when given for PCP prophylaxis. In Program and Abstracts of the 10th International Conference in AIDS, Yokohama, Japan, 1994. Abstract PB0611.
7. Gatti, G., Merighi, M., Hossein, J., Travaini, S., Casazza, R., Karlsson, M. et al. (1996). Population pharmacokinetics of dapsone administered biweekly to human immunodeficiency virus-infected patients. Antimicrobial Agents and Chemotherapy 40, 2743-8.
8. Derouin, F., Piketty, C., Chastang, C., Chau, F., Rouviex, B. & Pocidalo, J. J. (1991). Anti-Toxoplasma effects of dapsone alone and combined with pyrimethamine. Antimicrobial Agents and Chemotherapy 35, 252-5.
9. Weiss, L. M., Harris, C., Berger, M., Tanowitz, H. B. & Wittner, M. (1988). Pyrimethamine concentrations in serum and cerebrospinal fluid during treatment of acute Toxoplasma encephalitis in patients with AIDS. Journal of Infectious Diseases 157, 580-3.
10. Falloon, J., Lavelle, J., Ogata-Arakaki, D., Byrne, A., Graziani, A., Morgan, A. et al. (1994). Pharmacokinetics and safety of weekly dapsone and dapsone plus pyrimethamine for prevention of pneumocystis pneumonia. Antimicrobial Agents and Chemotherapy 38, 1580-7.